Organisation paid for research Program year 2025 Source: CMS Open Payments

Collaborative Neuroscience Research

Neither a doctor nor a teaching hospital

Research payments

$432,655

56 payments

Through program year 2025, Collaborative Neuroscience Research is reported as receiving $432,655 in research payments, across 56 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $218,996 28
2024 Research $62,708 8
2023 Research $28,051 5
2022 Research $55,089 8
2021 Research $67,812 7

Breakdown

Who paid Research payments · program years 2021–2025
  1. AbbVie, Inc. $278,069 35 payments
  2. Vanda Pharmaceuticals Inc. $111,703 13 payments
  3. Genzyme Corporation $31,183 6 payments
  4. Genentech, Inc. $11,700 2 payments
Studies the money was for Research payments · program years 2021–2025
  1. Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) $121,615 11 payments
  2. Evaluating the Effects of Vqw-765 VS. Placebo in Performance Anxiety $110,760 12 payments
  3. Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine $42,158 11 payments
  4. M23-894 - Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) $34,876 2 payments
  5. A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis $21,219 3 payments
  6. Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity $16,000 1 payment
  7. Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder $15,032 2 payments
  8. M23-894 ABBV-932 Ph 2 BPD $13,626 1 payment
  9. Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) $12,305 1 payment
  10. A Phase 2B Efficacy Safety Trial of Prasinezumab in Patients With Early Parkinson S Disease $11,700 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record